title: Acute goserelin administration inhibits gonadotropin and androgen secretion in post-menopausal women with ovarian hyperandrogenism.
abstract: The aim of this study was to verify the effect of goserelin, a GnRH agonist, in women with post-menopausal virilization. Six patients with post-menopausal virilization and increase in 17-hydroxyprogesterone (17-OHP), total (TT) and free testosterone (FT) levels underwent single subcutaneous administration of goserelin, 3.6 mg. Serum 17-OHP, TT, FT, LH, FSH, E2, delta4 and 3alpha-andro-stanediol glucuronide levels were measured before and 4, 8 and 18 days after goserelin administration. Goserelin administration was followed by progressive inhibition of FSH and LH, which fell to premenopausal levels on day 18, and progressive normalization of androgen parameters. The low E2 levels recorded at baseline were further reduced by goserelin administration. Four patients then underwent ovariectomy while in two patients, rejecting surgical treatment, goserelin treatment was protracted up to 6 and 12 months, respectively, with remission of hyperandrogenism. This study shows that in post-menopausal patients with virilization GnRH agonist allows to confirm the diagnosis of gonadotropin-dependent ovarian hyperandrogenism: its administration induces inhibition of gonadotropin levels, normalization of androgen parameters, and remission of virilization when the treatment is protracted in patients waiting for surgery.
authors.affiliation: Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, University of Turin, Turin, Italy. cataldo.dibisceglie@unito.it
authors.forename: C
authors.initials: C
authors.lastname: Di Bisceglie
authors.forename: L
authors.initials: L
authors.lastname: Brocato
authors.forename: M
authors.initials: M
authors.lastname: Tagliabue
authors.forename: A
authors.initials: A
authors.lastname: Bertagna
authors.forename: L
authors.initials: L
authors.lastname: Gianotti
authors.forename: E
authors.initials: E
authors.lastname: Ghigo
authors.forename: C
authors.initials: C
authors.lastname: Manieri
mesh_terms: D000324:Adrenocorticotropic Hormone; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006062:Gonadotropins / Q000037:antagonists & inhibitors*; D006065:Gonadotropins, Pituitary / Q000037:antagonists & inhibitors; D017273:Goserelin / Q000008:administration & dosage*; D006801:Humans; D017588:Hyperandrogenism / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D017698:Postmenopause; D012074:Remission Induction; D014770:Virilism / Q000209:etiology
chemical_list: D000726:Androgen Antagonists; D006062:Gonadotropins; D006065:Gonadotropins, Pituitary; D017273:Goserelin; D000324:Adrenocorticotropic Hormone